PubMed Health⌕ Search

Biomedical subjects

G Coman

Publications and source records attributed to G Coman.

At least 37 records · Page 2Linked to original sources
PubMedDate not supplied

Highly active effect of alpha interferon in blocking the cutaneous delayed hypersensitivity.

A group of 13 patients with contact dermatitis to various chemical compounds such as potassium dichromate, nickel sulphate, formaldehyde and balsam of Peru, was investigated by patch test and by the agreement between the history of disease and the patch test, the specific allergen involved in each special case could be demonstrated. Two-three days after the first patch test three normal skin areas were chosen. The first area was intradermally infiltrated with alpha-2a Interferon (IFN) (100,000 I.U. in 1 ml), the second area was infiltrated with saline and the third area, considered as control, did not receive any treatment. Once more the corresponding allergen was applied into the skin in a second patch-test. After 48 hours in the IFN infiltrated area, only the delayed contact hypersensitivity become negative thus proving that alpha-2a IFN behaves as an efficient inhibitor of these immune effector reactions. Since the lymphocytes involved in the delayed type hypersensitivity reactions (in our case contact dermatitis) belong to the T helper line, i.e., are CD-4 positive cells we conclude that alpha-2a IFN in vivo is an efficient inhibitor of the activation of these cells. This effect achieved by any CD-4(+) DTH clones does not depend on their antigenic specificity. Some clinical trials are now in progress in our laboratory to turn to account this important biological effect in the clinical practice as an efficient inhibitor in skin contact dermatitis.

Adolescent↗
PubMedDate not supplied

Therapeutic effect of intralesional interferon (Roferon) in squamous cell carcinoma.

Recombinant alpha-2 interferon (IFN)--Roferon--100,000 IU/ml was intralesionally administered in 8 cases of squamous cell carcinoma (SCC) three times a week during 4-6 weeks in inoculations of 1 ml each. The therapeutic effect was scored as major--more than 60% reduction of the tumor size, moderate--30-60% reduction of the tumor mass and, nonreactive--less than 30% reduction of the tumor size. Three cases showed a major reduction, three showed a moderate reduction and two patients showed no reduction of the tumor volume. Histopathological examination of the surgically removed tumors after completion of the Roferon administration confirmed the clinical diagnosis of squamous cell carcinoma and revealed that an intense leukocyte, mainly lymphocytes, infiltration can be observed along with necrotic centers, progressively surrounding and reducing in size the tumor islets, thus proving an intense activation of the immune effector reactions against tumor cells.

Carcinoma, Squamous Cell↗
PubMedDate not supplied

Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus.

In our study we have investigated the presence of apoptotic bodies, soluble FAS receptor and TNF (tumor necrosis factor) in three clinical forms of lupus erythematosus. Determinations were performed in attack period of: systemic lupus erythematosus (SLE) for 20 patients, 20 patients with subacute cutaneous lupus erythematosus (SCLE), 20 patients with chronic discoid lupus erythematosus (DLE). Determinations were performed by ELISA (for apoptotic bodies, kit Boehringer, normal values 400-800 mU), (for sFAS, kit R&D Systems, normal values 4500-17000 pg/ml) (for TNF, ELISA kit R&D Systems, normal values 0.4-3.6 pg/ml). Results in SLE: apoptotic bodies were increased in 16 cases (980-1030); sFAS in 18 cases (17000-24000 pg/ml) TNF was increased in all 20 cases (40-140 pg/ml). In SCLE with multiple cutaneous lesions and without internal organs disturbance the apoptotic bodies were increased in 10 cases (960-1030 pg/ml), sFAS in 9 cases (17000-22000 pg/ml), and TNF alpha in 9 cases. In DLE, apoptotic bodies were increased in 2 patients (980-1010 pg/ml), sFAS in 3 patients (17000-20000 pg/ml) and TNF in 2 patients (20-40 pg/mil). Investigated values were slightly correlated with immune parameters (anti dsDNA antibodies), but they were correlated with the presence of renal disturbances or extension of cutaneous lesions. We consider that the presence of increased apoptotic bodies as a result of peripheral mononuclear cells apoptosis appear as a nauto-limiting mechanism in a pathological immune response. The increase of sFAS in lupus patients serum might be interpreted as an alteration of apoptosis respectively a deficit in apoptosis which has as a first consequence the persistence of B and T lymphocytes, activated, in the pathogen immune response.

Apoptosis↗
PubMedDate not supplied

Human leukocyte interferon treatment associated with IL-2 in the non-AIDS related Kaposi's sarcoma.

Patients with classical European Kaposi's sarcoma have been treated by intra- and peritumoral injections of human alpha-leukocyte interferon (IFN) (12 cases) or alternatively with IFN and naturally synthetized IL-2 (8 cases). All the patients were HIV negative their tumour appearing at least six months before. In each patient one tumour received 1 ml (50,000 IU) IFM alone or associated, alternatively with 1 ml IL-2, twice a week during 4-6 weeks, whereas another nodule situated 8-10 cm apart was considered as control and remained uninjected. The clinical follow-up revealed that in the same patient in the same anatomical area the treated nodule was cured in all the investigated cases while the untreated nodule was not. These data undoubtedly prove that IFN is the responsible factor for the involution and final cure of the Kaposi tumours treated by perilesional inoculations. Association with IL-2 (and certainly also other interleukins) increases the beneficial clinical effect activating the tumour involution. The histological examination showed that important histopathological changes occur in the treated nodules, i.e., complete disappearance of the Kaposi's aspect; fibrosclerous modifications progressively replacing the abundant fibroblastic cells characteristic of Kaposi's tumour; abundant infiltrations of leukocytes especially lymphocytes; necrotic patches often appearing along with hemorrhagic centers. IL-2 association seems to frequently induce especially this last type of histological phenomena.

Adult↗
PubMedDate not supplied

Intralesional human leukocyte interferon treatment in the non-AIDS related Kaposi's sarcoma.

Twelve patients with classical European Kaposi's sarcoma have been treated by intra- and peritumoral injections of human alpha leukocyte interferon (IFN)--Ginterferon ("V. Babeş Institute", Bucharest). All the patients were HIV negative their tumour appearing at least six months before. In each patient one tumour received 1 ml (50,000 IU) IFN twice a week during 6-7 weeks whereas another nodule considered as control remained uninjected. After treatment biopsies of both the IFN-treated and the untreated nodules were performed in 8 patients and histological examinations were carried out. The clinical follow-up revealed: The skin colour progressively changed from purple red to dark reddish or even brown in all the IFN-treated tumours and only in 3 of the untreated ones (p less than 0.001). The consistency of the nodules decreased in all the treated tumours and only in 2 of the untreated ones (p less than 0.001). The tumour thickness decreased in 9 of the treated tumours and in none of the untreated ones (p less than 0.001). The surface of the lesions decreased in 4 of the treated nodules but not in the untreated ones (p less than 0.05). The IFN-inoculated tumours were gradually cured even in the four cases in which during the treatment some other tumour progressed or even new lesions appeared. The histological examination showed that: all the IFN-treated tumours were either predominantly sarcomatous or predominantly angiomatous. The typical Kaposi aspect disappeared totally in 2 of the cases examined, and in 3 a fibrosclerotic massive change was obvious.(ABSTRACT TRUNCATED AT 250 WORDS)

Acquired Immunodeficiency Syndrome↗
PubMedDate not supplied

Interferon efficiency in the treatment of herpetic dermatites. II. Comparison between human leukocyte interferon (Ginterferon) and a recombinant interferon (Roferon).

The comparative efficiency of a recombinant interferon-Roferon (R-IFN) and a human, naturally synthetized interferon-Ginterferon (G-IFN), applied as ointments in the treatment of herpetic dermatites, was studied in a blind trial. It was found that R-IFN in doses of 20,000 IU/g has practically similar results as G-IFN in doses of 10,000 IU/g therefore half the dose of the former product. Thus both preparations reduced significantly the mean duration of a herpetic dermatitis attack and both proved more efficient on smaller lesions (less than 2 sq.cm) than on larger ones (over 2 sq.cm). Likewise with both preparations the reduction of the healing period was more marked when administered in the first 2-3 days after onset. It was also found that the arrest of new vesicle appearance after two days of treatment is a reliable clinical criterion for the estimation of IFN capacity to block effectively viral multiplication in the host's epithelial cells. Finally the efficacy of both R-IFN and G-IFN proved similar whatever the localization of disease (oral or genital) or in their capacity to prevent relapses or the appearance of bacterial complications.

Clinical Trials as Topic↗
PubMedDate not supplied

Interferon efficiency in the treatment of herpetic dermatites. I. A double-blind placebo controlled study.

The effect of an alpha human leukocyte interferon (IFN) locally applied as an ointment in herpetic dermatitis was investigated in a double blind trial. It was observed that IFN reduced significantly by 25-42% the mean healing period of attacks. This reduction was more important if the period till disappearance of vesicles was considered than if the period till complete epithelialization was taken into consideration. Likewise IFN was proved more effective if administered within the first 2-3 days after onset of attacks than 5 days after. As compared with the group which received placebo the effect of IFN was more marked when the size of the lesions was smaller than 2 sq. cm. IFN did not reduce significantly the number of cases with bacterial superinfections nor the rate of relapses in the first three months after treatment. These results suggest that alpha IFN administered as an ointment is an efficient agent in blocking viral multiplication and therefore useful in the treatment of herpetic dermatitides whatever their localization.

Clinical Trials as Topic↗